This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents. Top assignee: Other. Active years: 2001-2004.
Location History:
- Chicoutimi, Québec, CA (2001)
- Chicoutimi, CA (2003 - 2004)
Company Filing History:
4 out of 834,411 Years Active: 2001-2004
Title: The Innovations of Daniel Gaudet
Introduction
Daniel Gaudet is a notable inventor based in Chicoutimi, Canada. He has made significant contributions to the field of genetics and metabolic disorders, holding a total of four patents. His work focuses on understanding the genetic factors that influence conditions such as glucose tolerance and type 2 diabetes mellitus.
Latest Patents
One of Gaudet's latest patents is titled "Very low density lipoprotein receptor polymorphisms and uses therefor." This patent describes polymorphic nucleic acid molecules that encode the very low density lipoprotein receptor. It also includes allele-specific primers and probes that hybridize to regions flanking or containing these sites, along with methods of use. Another significant patent is "Glycerol as a predictor of glucose tolerance," which details novel alterations in the glycerol kinase gene. This patent outlines methods for predicting or assisting in the prediction of impaired glucose tolerance and type 2 diabetes mellitus.
Career Highlights
Throughout his career, Daniel Gaudet has worked with various organizations, contributing to advancements in genetic research. His innovative approaches have led to a deeper understanding of metabolic conditions, which can have a profound impact on public health.
Collaborations
Gaudet has collaborated with esteemed colleagues such as Thomas J. Hudson and Marie-Claude Vohl. These partnerships have enhanced the quality and reach of his research, allowing for a more comprehensive exploration of genetic factors in health.
Conclusion
Daniel Gaudet's work exemplifies the intersection of innovation and health science. His patents reflect a commitment to advancing our understanding of genetic influences on metabolic disorders. Through his research, he continues to contribute valuable insights that may lead to improved health outcomes.